Roche announced on Tuesday that it will once again partner with PathAI, a specialist in artificial intelligence applied to pathology, this time in the field of therapy-accompanying diagnostics.

Under the terms of the agreement, PathAI will collaborate exclusively with Roche Tissue Diagnostics (RTD), the instruments and reagents business enabling the diagnosis of cancer and infectious diseases through the analysis of human tissue.

The aim of the partnership is to design AI-powered digital pathology algorithms for Roche's companion tests, which help determine which patients are likely to benefit from a given treatment.

Following a previous project in 2021, Roche and PathAI had already jointly developed an embedded medical imaging analysis tool for pathologists, now integrated into Roche's navify platform.

Copyright (c) 2024 CercleFinance.com. All rights reserved.